[{"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (delivered dose 320\u2009\u03bcg/9\u2009\u03bcg) is recommended for the symptomatic treatment of adult patients with severe COPD (forced expiratory volume in 1 second <50% of predicted value) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (320\u2009\u03bcg/9\u2009\u03bcg twice daily) was effective and well tolerated in adult patients with moderate to severe COPD participating in large, multicentre trials of up to 12 months' duration. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (delivered dose 320\u2009\u03bcg/9\u2009\u03bcg) is recommended for the symptomatic treatment of adult patients with severe COPD (forced expiratory volume in 1 second <50% of predicted value) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (320\u2009\u03bcg/9\u2009\u03bcg twice daily) was effective and well tolerated in adult patients with moderate to severe COPD participating in large, multicentre trials of up to 12 months' duration. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": " Budesonide/formoterol (BF) is available in two delivery systems, the dry powder inhaler (DPI) Turbuhaler and a pressurized metered dose inhaler (pMDI) for use in patients with asthma or chronic obstructive pulmonary disease (COPD). "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "AIM: To study the effects of addition of Theophylline to the combination of Formoterol plus Budesonide on various objective and subjective parameters in moderate to severe COPD patients and to assess the safety profile of the combination. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Addition of Theophylline to Formoterol plus Budesonide reduces dyspnea, improves exercise performance and pulmonary functions in moderate to severe COPD. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSIONS: Budesonide/formoterol 160/4.5\u2009\u03bcg two inhalations twice daily was effective and well tolerated in patients with moderate to severe COPD, offering benefits over formoterol alone in terms of improved lung function and reduced risk of exacerbation. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSIONS: Budesonide/formoterol has a fast onset of bronchodilation effect in patients with moderate-severe COPD and asthma. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "The gas flow rate and volume responses in patients with COPD differ from those with asthma after inhalation of Budesonide/formoterol. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNF\u03b1) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide is widely used for COPD treatment as anti-inflammatory drug. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (delivered dose 320\u2009\u03bcg/9\u2009\u03bcg) is recommended for the symptomatic treatment of adult patients with severe COPD (forced expiratory volume in 1 second <50% of predicted value) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae (320\u2009\u03bcg/9\u2009\u03bcg twice daily) was effective and well tolerated in adult patients with moderate to severe COPD participating in large, multicentre trials of up to 12 months' duration. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol pMDI is an appropriate treatment for reducing exacerbations in COPD patients with a history of exacerbations. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol added to tiotropium was the dominant strategy compared with placebo added to tiotropium based on a 12-week study in COPD patients eligible for ICS/LABA combination therapy in Australia and Canada, and appears to be a cost-effective strategy in Sweden. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide, formoterol or azithromycin did not suppress phagocytosis suggesting that reduced responses in COPD MDM were not due to medications. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "INTERPRETATION: Budesonide treatment for 12 months does not increase the risk of pneumonia in patients with COPD during that time and therefore is safe for clinical use in such patients. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol pMDI was also associated with improvements from baseline in other measures of lung function, COPD control (including the time to first COPD exacerbation in the 12-month trial), symptoms and health status. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol pMDI was well tolerated in clinical trials in patients with COPD. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide (BUD) and formoterol (FORM) synergize in controlling asthma and COPD exacerbations; however, their effects on virus-induced inflammation and remodelling are less known. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSIONS: Budesonide/formoterol pMDI (320/9 microg and 160/9 microg) improved pulmonary function and reduced symptoms and exacerbations over 1 year in patients with moderate to very severe COPD. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide and formoterol AUC were 12% and 15% higher in COPD versus asthma patients. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol has an onset of bronchodilatory effect in patients with COPD and reversible airway obstruction that is faster than salmeterol/fluticasone and similar to salbutamol. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol is a combination inhaled steroid and long-acting bronchodilator delivered by a dry-powder inhaler, approved for use in COPD. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol in patients with severe COPD (GOLD stages III or IV) may be cost effective, from the healthcare provider perspective, compared with either monocomponent. "}, {"drug": "Budesonide", "polarity": 1, "disease": "COPD", "orig_sen": "Budesonide/formoterol was generally well tolerated by patients with severe COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "METHODS: A post hoc analysis of a previous prospective randomized study was performed for COPD patients using higher dose (HD: Fluticasone 1,000 \u03bcg/day) or medium dose (MD: Fluticasone 500 \u03bcg/day) of ICS combined with Salmeterol (100 \u03bcg/day). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " The Indacaterol: Switching Non-exacerbating Patients with Moderate COPD From Salmeterol/Fluticasone to Indacaterol (INSTEAD) study investigated the effect of switching patients at low risk of chronic obstructive pulmonary disease (COPD) exacerbations from salmeterol/fluticasone (SFC; inhaled corticosteroid (ICS) regimen) to indacaterol monotherapy (non-ICS regimen). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " BACKGROUND: Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects and improves clinical symptoms in patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " Salmeterol/fluticasone propionate (Seretide, Advair, Viani) administered using a multidose dry powder inhaler (Diskus, Accuhaler) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries.Salmeterol/fluticasone propionate administered twice daily via dry powder inhaler is effective and generally well tolerated in patients with COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol/fluticasone improves FEV1% in mild and moderate more than in severe COPD patients. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol/fluticasone propionate 50/500 microg significantly reduced annual COPD exacerbations, especially in severe COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "The role of inhaled corticosteroids still remains controversial, but there is increasing evidence that they may improve FEV(1) and symptoms in the long-term.AIM: of the present small pilot study was to compare Salmeterol & Fluticasone (SM&FP) 50/250 microg bid via a single Diskus inhaler with SM 50 microg bid alone, and with placebo (P) in the treatment of moderate COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol has been shown to be an effective first-line bronchodilator in COPD and fluticasone has been shown to reduce the frequency and or severity of exacerbations in COPD patients in two key trials. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "METHODS: A post hoc analysis of a previous prospective randomized study was performed for COPD patients using higher dose (HD: Fluticasone 1,000 \u03bcg/day) or medium dose (MD: Fluticasone 500 \u03bcg/day) of ICS combined with Salmeterol (100 \u03bcg/day). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " The Indacaterol: Switching Non-exacerbating Patients with Moderate COPD From Salmeterol/Fluticasone to Indacaterol (INSTEAD) study investigated the effect of switching patients at low risk of chronic obstructive pulmonary disease (COPD) exacerbations from salmeterol/fluticasone (SFC; inhaled corticosteroid (ICS) regimen) to indacaterol monotherapy (non-ICS regimen). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "We tried a critical combination therapy for management of COPD.METHODS: Current or past smoker (passive or active) COPD patients with moderate to severe COPD who did not respond to primitive therapy (i.e., oral prednisolone (50 mg in the morning) for 5 days; with Beclomethasone Fort (3 puff q12h, totally 1500 micrograms/day), Salmeterol (2 puffs q12h, 50 micrograms/puff) and ipratropium bromide (4 puffs q8h) for two months, enrolled to study. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol appears to provide a protective effect, not related to bronchodilation, against an acute alveolar fluid clearance challenge secondary to lung fluid overload in COPD patients. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " BACKGROUND: Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects and improves clinical symptoms in patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol significantly reduced COPD exacerbations with both study arms exposed or not exposed to inhaled corticosteroids (ICS). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " Salmeterol/fluticasone propionate (Seretide, Advair, Viani) administered using a multidose dry powder inhaler (Diskus, Accuhaler) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries.Salmeterol/fluticasone propionate administered twice daily via dry powder inhaler is effective and generally well tolerated in patients with COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Salmeterol has a positive effect on symptoms and health status of patients with COPD when added to usual treatment. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "The results show a drop in COPD exacerbations in comparison to Ipratropium, Salmeterol and standard care (without use of anticholinergics and beta-adrenergics). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol/fluticasone improves FEV1% in mild and moderate more than in severe COPD patients. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol 50 microg twice daily and formoterol 12 microg twice daily are effective and safe in treating patients with asthma and COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol/fluticasone propionate 50/500 microg significantly reduced annual COPD exacerbations, especially in severe COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "The role of inhaled corticosteroids still remains controversial, but there is increasing evidence that they may improve FEV(1) and symptoms in the long-term.AIM: of the present small pilot study was to compare Salmeterol & Fluticasone (SM&FP) 50/250 microg bid via a single Diskus inhaler with SM 50 microg bid alone, and with placebo (P) in the treatment of moderate COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " BACKGROUND: Salmeterol has been shown a useful drug for the treatment of chronic obstructive pulmonary disease (COPD). "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSIONS: Salmeterol has a beneficial effect when added to existing anticholinergic therapy in patients with COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol has been shown to be an effective first-line bronchodilator in COPD and fluticasone has been shown to reduce the frequency and or severity of exacerbations in COPD patients in two key trials. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those \"unresponsive\" to albuterol. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " PURPOSE: To provide information on the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg (FSC MDI) and its comparable dose of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC DISKUS) in patients with COPD. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": " The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. "}, {"drug": "Salmeterol", "polarity": 1, "disease": "COPD", "orig_sen": "Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those \"unresponsive\" to albuterol. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-blind study to evaluate the efficacy and safety of two doses of fluticasone propionate/formoterol compared to formoterol monotherapy in COPD patients with FEV1 \u226550% predicted and a history of exacerbations. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": " Fluticasone propionate reduces the frequency and severity of the episodes of exacerbation of chronic obstructive pulmonary disease (COPD). "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol (Advair) or Seretide), GlaxoSmithKline) is a combination inhaled steroid and long-acting bronchodilator that is delivered by a dry-powder inhaler and was recently approved for use in COPD in the US. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol is a potent bronchodilator and also appears to have important effects on the frequency of exacerbations and overall quality of life for some patients with COPD. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Fluticasone propionate given for 3 months to patients with COPD has selective effects on the inflammatory cells in the bronchial mucosa: the reduction in mast cell numbers may account for the improvement in symptoms over this time. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "INTERPRETATION: Fluticasone propionate may be of clinical benefit in patients with COPD over at least 6 months. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": " PURPOSE: To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 \u03bcg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "CONCLUSION: Inhaled Salmeterol 50 \u03bcg and Fluticasone propionate 500 \u03bcg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": " Fluticasone propionate (FP) and Salmeterol (SAL) are commonly used in combination therapy for patients with Chronic obstructive pulmonary disease (COPD). "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol (Advair) or Seretide), GlaxoSmithKline) is a combination inhaled steroid and long-acting bronchodilator that is delivered by a dry-powder inhaler and was recently approved for use in COPD in the US. "}, {"drug": "Fluticasone propionate", "polarity": 1, "disease": "COPD", "orig_sen": "Fluticasone propionate/salmeterol is a potent bronchodilator and also appears to have important effects on the frequency of exacerbations and overall quality of life for some patients with COPD. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "The safety and efficacy of Albuterol compared to Albuterol/Ipratropium bromide as rescue medications for COPD patients on maintenance combination therapy of ICS/LABA has not been evaluated. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Albuterol inhalation increased mean Qaw significantly in lifetime nonsmokers (50.1 +/- 8.3% predicted; p < 0.05) and healthy ex-smokers (37.2 +/- 3.4% predicted; p < 0.05), but not in healthy current smokers (13.9 +/- 3.2% predicted; difference was not significant) and ex-smokers with COPD (9.7 +/- 4.5% predicted; difference was not significant). "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Albuterol inhalation increased mean Q(aw) in lifetime non-smokers (50.1+/-8.3%; p<0.05) and in healthy ex-smokers (37.2+/-3.4%; p<0.05) but not in healthy current smokers (13.9+/-3.2%; p=NS) and ex-smokers with COPD (9.7+/-4.5%; p=NS). "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "The safety and efficacy of Albuterol compared to Albuterol/Ipratropium bromide as rescue medications for COPD patients on maintenance combination therapy of ICS/LABA has not been evaluated. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "The safety and efficacy of Albuterol compared to Albuterol/Ipratropium bromide as rescue medications for COPD patients on maintenance combination therapy of ICS/LABA has not been evaluated. "}, {"drug": "Albuterol", "polarity": 1, "disease": "COPD", "orig_sen": "Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The aim of this study was to assess whether inhaled treatment with a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting \u03b2 agonist, vilanterol could improve survival compared with placebo in patients with moderate COPD and heightened cardiovascular risk. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " Identification of a biomarker that predicts response to inhaled corticosteroids (ICS) would help evaluate the risk/benefit profile of ICS in chronic obstructive pulmonary disease (COPD) and guide treatment.The ISOLDE study randomised 751 patients (mean post-bronchodilator forced expiratory volume in 1\u2009s (FEV1) 1.4\u2005L: 50% predicted normal) to fluticasone propionate 500\u2005\u03bcg twice daily or placebo for 3\u2005years, finding no difference in FEV1 rate of decline between treatments (p=0.16) and a significant reduction in median exacerbation rate with fluticasone propionate versus placebo (p=0.026). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Exacerbation rate reduction on ICS for fluticasone propionate versus placebo was higher in the eosinophil <2% group compared with the \u22652% group; time-to-first moderate/severe exacerbation was not different between treatments in either group.A baseline blood eosinophil count of \u22652% identifies a group of COPD patients with slower rates of decline in FEV1 when treated with ICS: prospective testing of this hypothesis is now warranted. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CLINICAL RELEVANCE: The results from these two studies demonstrate that the addition of umeclidinium (62.5 \u03bcg and 125 \u03bcg) to FF/VI (100/25 \u03bcg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50\u2005\u00b5g, once-daily tiotropium (TIO) 18\u2005\u00b5g or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500\u2005\u00b5g twice daily. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: One hundred fourteen patients with moderate to severe COPD finished randomized 6-month or 30-month treatment with fluticasone (500 \u03bcg bid), 30-month treatment with fluticasone and salmeterol (500/50 \u03bcg bid), or placebo (first part of the Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease [GLUCOLD] study [GL1]). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "We also used material from a previous double-blinded randomized placebo-controlled 6-month ICS intervention study in COPD patients to explore the effect of ICS on PAFr expression. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In phase 3 trials in patients with moderate to very severe COPD, overall, once-daily fluticasone furoate/vilanterol 100/25\u00a0\u00b5g improved pulmonary function more than placebo and fluticasone furoate alone and improved exacerbation rates more than vilanterol alone. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "COPD subjects were randomized to twice daily MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, MF 400\u00a0\u03bcg, F 10\u00a0\u03bcg, and placebo; asthma subjects were randomized to MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, fluticasone propionate/salmeterol (FP/S) 250/50\u00a0\u03bcg, and FP/S 500/50\u00a0\u03bcg. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients aged \u226540 years with moderate-to-very severe COPD were randomized to receive double-blind, double-dummy FF/VI 100/25 mcg once-daily, or FP/SAL 250/50 mcg twice-daily for 12 weeks following a 2 week placebo run-in period. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "With no data available on potential treatment effects, we undertook a blinded analysis of inhaled corticosteroids (ICS) effects versus placebo on EMT markers in previously obtained endobronchial biopsies in COPD patients, as a \"proof of concept\" study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Assessment of the effects of inhaled fluticasone propionate (FP; 500 \u03bcg twice daily for 6 months) versus placebo in 34 COPD patients (23 on fluticasone propionate and eleven on placebo). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: To determine the efficacy and safety of combined ICS and LABA for stable COPD in comparison with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "AUTHORS' CONCLUSIONS: Combined inhaler therapy led to around a quarter fewer COPD exacerbations than were seen with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 \u03bcg, FP 500 \u03bcg, salmeterol xinafoate (SLM) 50 \u03bcg, and combination FP 100 \u03bcg + SLM 50 \u03bcg. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Whole-genome gene expression profiling using the Affymetrix Gene ST array (V.1.0) was performed on 221 bronchial biopsies available from 89 COPD patients at baseline and after 6 and 30 months of fluticasone\u00b1salmeterol and placebo treatment in GLUCOLD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: 23 mild asthmatic and 24 COPD subjects with documented AHR to both AMP and methacholine took part in a randomized, double-blind, placebo-controlled, crossover study to measure AHR to inhaled AMP and methacholine 2 h after either 1000 \u03bcg FP or matched placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Change in the airways response to inhaled AMP after FP was well within test variability in patients with COPD, with PC20AMP values 59.6 (11.3-183.9) and 76.3 (21.0-445.3) (p = 0.022; post-placebo vs post-FP) mg/ml. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "A change in doubling dilution, between placebo and following a single dose of FP, in AMP had a better sensitivity and specificity of 95.8% and 65.2%, compared to methacholine of 79.2% and 43.5% respectively in delineating between COPD and asthma. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVE: To compare major extracellular matrix components (elastic fibers; proteoglycans [versican, decorin]; collagens type I and III) in bronchial biopsies 1) after 30-months inhaled steroids treatment or placebo; and 2) between current and ex-smokers with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Multicentre, randomised, placebo-controlled, double-blind, parallel-group study of patients (N\u00a0=\u00a01030) with moderate-to-severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Multicentre, randomised, 24-week, double-blind, placebo-controlled, parallel-group study in stable, moderate-to-severe COPD subjects (N = 1224). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "SUMMIT is a multicentre, randomised, double-blind, parallel-group, placebo-controlled trial of 16 000 patients with moderate COPD randomly assigned to once daily treatment with fluticasone furoate/vilanterol (100/25 \u03bcg), fluticasone furoate (100 \u03bcg), vilanterol (25 \u03bcg) or matched placebo; mortality is the primary end-point. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Moreover, we showed that MRP1 variants are also associated with FEV(1) level and inflammatory markers in COPD patients.We investigate in the current study the association of MRP1 protein expression in bronchial biopsies with FEV(1) decline in COPD patients using placebo, or inhaled corticosteroids (ICS) with or without long-acting \u03b22-agonists. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: A retrospective analysis evaluated all double-blind, placebo-controlled, trials in patients \u22654 years of age involving budesonide or budesonide/formoterol in asthma (26 trials; budesonide: n\u00a0=\u00a09067; placebo: n\u00a0=\u00a05926), and in COPD (8 trials; budesonide: n\u00a0=\u00a04616; non-ICS: n\u00a0=\u00a03643). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Fifteen randomized, placebo-controlled clinical trials including COPD patients were evaluated: indacaterol 75 \u03bcg once daily (n = 2 studies), indacaterol 150 \u03bcg once daily (n = 5), indacaterol 300 \u03bcg once daily (n = 4), FOR/BUD 9/160 \u03bcg twice daily (n = 2), FOR/BUD 9/320 \u03bcg twice daily (n = 2), SAL/FP 50/500 \u03bcg twice daily (n = 4), and SAL/FP 50/250 \u03bcg twice daily (n = 1). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Results from Phase II studies have shown clinically and statistically significant improvements over placebo in trough (24-hour postdose) forced expiratory volume in 1 second (FEV(1)) after once-daily dosing with FF or VI (VI concurrently with an inhaled corticosteroid) in asthma and VI in COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: This Phase III, multicenter, randomized, double-blind, placebo-controlled study was designed based on guidance from drug regulators with the goal of evaluating the 24-hour spirometric effect of once-daily FF/VI in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "I selected 16 randomized, placebo-controlled, blinded, long-term studies, mostly carried out in asthma (n = 14) and COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Methods Participants were patients with moderate-to-severe COPD treated with placebo or FF/VI 400/25 \u03bcg OD for 4 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Conclusion FF/VI has a good safety and tolerability profile and improves lung function compared with placebo in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Shorter-term placebo-controlled trials in patients with COPD demonstrated significantly higher trough forced expiratory volume in 1 second (FEV(1)) responses with tiotropium bromide than with placebo, confirming it has a duration of action of \u226524 hours and is suitable for once-daily administration. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The large, 4-year UPLIFT\u00ae trial did not show a significant reduction in the annual rate of decline in FEV(1) with tiotropium bromide versus placebo in patients with COPD, although subgroup analyses demonstrated a significantly lower rate of decline with tiotropium bromide than with placebo in some patient groups (e.g. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Tiotropium bromide prevented exacerbations in patients with COPD, with a significantly lower exacerbation rate and a significantly longer time to first exacerbation seen with tiotropium bromide than with placebo or salmeterol. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 \u00b5g/500 \u00b5g combination (SFC), or placebo in a 12-week, randomized, double-blind, double-dummy study (MKI102428/NCT00642148). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: This was a randomized, double-blind, placebo-controlled, crossover study (NCT00387036) to compare the effects of inhaled fluticasone propionate 500 \u03bcg (FP500) twice-daily and placebo (PLA) on airway function during rest and exercise, measured during constant work rate cycle exercise at 75% of maximum incremental cycle work rate, in 17 patients with COPD (FEV(1) \u2264 70% predicted). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: this study compared the onset of action of single doses of indacaterol 150 and 300 \u03bcg with salbutamol 200 \u03bcg, salmeterol-fluticasone 50/500 \u03bcg, and placebo in moderate-to-severe COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In chronic respiratory diseases in general, and chronic obstructive pulmonary disease (COPD) in particular, adherence to inhaled therapy can potentially influence disease prognosis, as demonstrated in the analyses discussed in this article and a 3-year study assessing the effects of inhaled salmeterol, inhaled fluticasone and an inhaled combination over placebo in patients with moderate-to-severe COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: To test the hypothesis that ICS and theophylline have a greater therapeutic effect than theophylline alone, 30 patients with COPD were treated with placebo theophylline capsules and either inhaled fluticasone propionate (FP) (500 microg bid) or inhaled placebo for 4 weeks in a double-dummy, randomized, double-blind, parallel study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " The TOwards a Revolution in COPD Health (TORCH) study was a 3-yr multicentre trial of 6,112 patients randomised to salmeterol (Salm), fluticasone propionate (FP), a Salm/FP combination (SFC) or placebo (P). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial was a RCT comparing tiotropium and placebo in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: TORCH was a 3-year, double-blind, placebo-controlled trial of 6112 patients with moderate/severe COPD with pre-bronchodilator FEV1 < 60% predicted (mean age 65 years, 76% male, mean 44% predicted FEV1, 43% current smokers). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHOD: We used data from 41 patients with a history of stable moderate COPD (average age 64 years) who were randomised to inhaled fluticasone (500 microg twice daily from a Diskus inhaler), oral prednisone (30 mg daily) or placebo for 2 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a post hoc analysis of the TOwards a Revolution in COPD Health (TORCH) study, we analysed and identified potential risk factors for adverse event reports of pneumonia in this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 microg, fluticasone propionate (FP) 500 microg, and the combination (SFC) with placebo in 6,184 patients with moderate-to-severe COPD over 3 yrs. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "STUDY DESIGN: A Markov model was constructed to estimate the incremental quality-adjusted life-years (QALYs) gained of the alternative treatment arms used in the Towards a Revolution in COPD Health (TORCH) study (ie, salmeterol-fluticasone propionate combination [SFC], salmeterol, fluticasone, and placebo). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Four prospective placebo-controlled clinical trials of 2-6 years duration with inhaled budesonide in patients with asthma or COPD were found. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: A double-blind, placebo-controlled, randomized 2:1 study of fluticasone propionate (FP), 500 microg twice daily versus placebo over 6 months was performed in subjects with mild to moderate COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " The Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study was a trial that randomised 752 patients with moderate to severe COPD to fluticasone propionate 1000 mcg/day or placebo for three years. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "An increased risk of pneumonia with inhaled corticosteroids was first reported from the Toward Revolution in COPD Health (TORCH) study, a large randomized clinical trial comparing fluticasone, salmeterol, or a combination of the two medications with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Several large-scale studies in patients with moderate-to-severe COPD have demonstrated that treatment with SFC and FBC leads to significantly greater improvements in lung function, exacerbations, health status and breathlessness, compared with placebo or monotherapy with the component drugs. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: In a pragmatic randomised, double-blind, placebo-controlled trial in 31 practices, 260 COPD patients stopped their usual ICS (median duration of use 8 years) and were allocated to 500 mcg fluticasone propionate twice daily (n = 128), or placebo (n = 132). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "RESULTS: In patients randomised to placebo, COPD exacerbation risk over one year was RR: 1.11 (CI: 0.91-1.36). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a post-hoc analysis, patients with mild COPD taking placebo had increased exacerbation risk RR: 1.94 (CI: 1.20-3.14). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In studies of FP or of Sal/FP in COPD, there was a reduction in all-cause mortality by 25% relative to placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Three 1-year randomized clinical trials, which studied the effect of combining a long-acting beta2-agonist with an inhaled corticosteroid in COPD, documented that exacerbation frequency was lower with therapy than placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Recently, a worldwide double-blind placebo-controlled study 'Towards a revolution in COPD health' (TORCH) was published in which salmeterol 50 microg and fluticasone 500 microg twice daily was compared with placebo, salmeterol alone or fluticasone alone. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "George Respiratory Questionnaire (SGRQ) scores, relief bronchodilator use, nighttime awakenings, and frequency of exacerbations of COPD were measured in patients randomized to receive SFC (n = 297) or placebo (n = 148). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The adjusted ratio of exacerbations of COPD for the SFC group relative to the placebo group was 0.61 (95% CI, approximately 0.45 to 0.84; p < 0.01). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Four double-blind, placebo-controlled, randomized clinical trials have demonstrated that salmeterol/fluticasone propionate improves pulmonary function and health status, and also decreases exacerbation rates in COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " The TORCH study (Towards a Revolution in COPD Health) was a double-blind, randomised, placebo-controlled clinical trial, investigating the combination of salmeterol/fluticasone propionate for 3 years in COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " BACKGROUND: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Tiotropium plus fluticasone-salmeterol improved lung function (P = 0.049) and disease-specific quality of life (P = 0.01) and reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53 [CI, 0.33 to 0.86]) and all-cause hospitalizations (incidence rate ratio, 0.67 [CI, 0.45 to 0.99]) compared with tiotropium plus placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "A recent individual patient-based meta-analysis of randomized, placebo-controlled trials of inhaled corticosteroids in COPD indicated that mortality over 3-4 yr was 27% lower in the group that received inhaled corticosteroids compared with the group that received placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "To prove the concept that inhaled corticosteroids could suppress systemic inflammation (as exemplified by serum C-reactive protein [CRP] levels), a double-blind, placebo-controlled clinical trial was conducted in a group of patients with mild to moderate COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "budesonide 800 microg/day or fluticasone propionate 1 mg/day) reduce exacerbations by 20-30% and improve the health status of COPD patients by a similar amount compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: The Canadian Optimal Therapy of COPD Trial is a randomized, prospective, double-blind, placebo-controlled, multicentre trial funded by the Canadian Institutes of Health Research that has been designed to determine which combination of inhaled medications will most effectively prevent exacerbations and optimize disease-specific quality of life in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The study will randomize 432 patients with moderate to severe COPD to one of three parallel treatment arms for 52 weeks: tiotropium and fluticasone/salmeterol; tiotropium and salmeterol; or tiotropium and placebo inhaler. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSION: The present randomized, placebo-controlled trial offers a unique opportunity to answer the question, what is the best combination of inhaled medications to use for COPD patients? It is hoped that optimal use of inhaled medications will improve patient health and quality of life, reduce patient respiratory exacerbations, and ultimately, reduce health care resource use. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In this study, we have performed additional analyses of the combined data from two previous double-blind, placebo-controlled, parallel studies of salmeterol (50 microg, b.i.d) in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a sensitivity analysis, we compared 539 male and 180 female COPD patients, who were randomized to the saLmeterol/fluticasone combination 50/500mcg bid or placebo for 12 months. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Some corticosteroid-related adverse events were increased in recipients of fluticasone propionate with or without salmeterol versus salmeterol monotherapy or placebo; withdrawal from fluticasone propionate, including combination therapy, needs careful management to minimise COPD exacerbations. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In three randomized, double-blind, 24-week or 52-week studies in >2850 patients with chronic obstructive pulmonary disease (COPD), administration of salmeterol/fluticasone propionate 50/250 microg twice daily (in one study) and salmeterol/fluticasone propionate 50/500 microg twice daily (in the other studies) provided greater improvement in lung function than placebo or either component alone at the same nominal dosage. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " STUDY OBJECTIVES: To compare the efficacy and safety of the inhaled corticosteroid fluticasone propionate (FP) and the inhaled long-acting beta(2)-agonist salmeterol (SM), when administered together in a single device (Diskus; GlaxoSmithKline, Inc; Research Triangle Park, NC), with that of placebo and the individual agents alone in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Oral prednisolone 0.6 mg/kg was given for 14 days to 524 patients with COPD before randomised treatment for 3 years with fluticasone propionate or placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The role of inhaled corticosteroids still remains controversial, but there is increasing evidence that they may improve FEV(1) and symptoms in the long-term.AIM: of the present small pilot study was to compare Salmeterol & Fluticasone (SM&FP) 50/250 microg bid via a single Diskus inhaler with SM 50 microg bid alone, and with placebo (P) in the treatment of moderate COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: An economic analysis was performed in a 6-month, randomized, double-blind clinical trial comparing FP 1,000 microg/day with placebo in 281 patients aged 45-79 years with symptomatic moderate-to-severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) study in COPD showed a 26% reduction in the yearly rate of exacerbations in patients treated with fluticasone propionate (FP) compared to placebo, but did not indicate which patients showed greatest benefit. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "A total of 691 patients with COPD received the combination of F and S (FSC), S (50 mcg), F (500 mcg), or placebo twice daily via the Diskus device for 24 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients had mild to moderately severe COPD (FEV(1) 25-80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 micro g twice daily, n=14) or placebo (n=10). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSION: In patients with COPD and BHR, FP has a positive effect on indices of lung function compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "We have performed a double-blind, placebo-controlled, randomized study to compare fluticasone propionate (FP) 500 microg twice daily via a dry powder inhaler and placebo (P) over a 3-month period in subjects with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Forty-eight adult subjects with \"early signs of COPD\" (slightly increased forced expiratory volume in 1 sec [FEV1] decline of >0.04L/year) and 29 adult subjects with \"early signs of asthma\" (signs of bronchial hyperresponsiveness or reversibility) participated in a randomized placebo-controlled trial with FP (Flixotide 500 microg daily) versus placebo with a duration of 2 years or 1 year, respectively. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "During the FP-treatment of COPD patients, FEV1 remained stable, while FEV1 deteriorated significantly in the placebo group. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " BACKGROUND: The efficacy of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease (COPD) remains controversial because of a lack of placebo-controlled studies. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "We compared the effect of inhaled fluticasone propionate with placebo in the treatment of patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: A meta-analysis of randomized, double-blind, parallel-group, placebo-controlled trials for LABA treatment of COPD with at least 3 months of follow-up was performed. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Compared with placebo, inhaled LABAs significantly decreased fatal cardiovascular adverse events in COPD patients (RR 0.65, 95% CI 0.50 to 0.86, P = 0.002). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50\u2005\u00b5g, once-daily tiotropium (TIO) 18\u2005\u00b5g or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500\u2005\u00b5g twice daily. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a phase 2b trial, batefenterol produced statistical and clinically significant differences compared to placebo and numerically greater improvements in the primary end point of trough FEV1 compared to salmeterol after 4 weeks of dosing in patients with moderate to severe chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: To compare the efficacy and safety of indacaterol versus placebo and alternative twice-daily long-acting beta2-agonists for the treatment of patients with stable COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "AUTHORS' CONCLUSIONS: For patients with stable COPD, use of indacaterol versus placebo results in statistically significant and clinically meaningful improvements in lung function and quality of life. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In phase 3 trials in patients with moderate to very severe COPD, overall, once-daily fluticasone furoate/vilanterol 100/25\u00a0\u00b5g improved pulmonary function more than placebo and fluticasone furoate alone and improved exacerbation rates more than vilanterol alone. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "COPD subjects were randomized to twice daily MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, MF 400\u00a0\u03bcg, F 10\u00a0\u03bcg, and placebo; asthma subjects were randomized to MF/F 200/10\u00a0\u03bcg, MF/F 400/10\u00a0\u03bcg, fluticasone propionate/salmeterol (FP/S) 250/50\u00a0\u03bcg, and FP/S 500/50\u00a0\u03bcg. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients aged \u226540 years with moderate-to-very severe COPD were randomized to receive double-blind, double-dummy FF/VI 100/25 mcg once-daily, or FP/SAL 250/50 mcg twice-daily for 12 weeks following a 2 week placebo run-in period. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "placebo in patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: To determine the efficacy and safety of combined ICS and LABA for stable COPD in comparison with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "AUTHORS' CONCLUSIONS: Combined inhaler therapy led to around a quarter fewer COPD exacerbations than were seen with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: To assess the effects of twice-daily long-acting beta2-agonists compared with placebo for patients with COPD on the basis of\u00a0clinically important\u00a0endpoints, primarily quality of life and COPD exacerbations. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "MAIN RESULTS: Twenty-six RCTs met the inclusion criteria, randomly assigning 14,939 people with COPD to receive twice-daily LABA or placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The objective of this study is to evaluate the comparative efficacy of indacaterol 75/150/300\u00a0\u03bcg once daily (OD), glycopyrronium bromide 50\u00a0\u03bcg OD, tiotropium bromide 18\u00a0\u03bcg/5\u00a0\u03bcg OD, salmeterol 50\u00a0\u03bcg twice daily (BID), formoterol 12\u00a0\u03bcg BID, and placebo for moderate to severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 \u03bcg, FP 500 \u03bcg, salmeterol xinafoate (SLM) 50 \u03bcg, and combination FP 100 \u03bcg + SLM 50 \u03bcg. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In long-term clinical studies (12 weeks to 1 year) in patients with moderate to severe COPD, OD indacaterol 150 or 300 \u03bcg improved lung function (primary endpoint) significantly more than placebo, and improvements were significantly greater than twice-daily formoterol 12 \u03bcg or salmeterol 50 \u03bcg, and noninferior to OD tiotropium bromide 18 \u03bcg. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Several phase III studies have shown that indacaterol 150 \u00b5g improves lung function, breathlessness, health status, exacerbations, rescue medication use and symptoms, as compared with placebo and other bronchodilators, in patients with COPD, with a rapid onset of action following first dose and a good safety and tolerability profile. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Whole-genome gene expression profiling using the Affymetrix Gene ST array (V.1.0) was performed on 221 bronchial biopsies available from 89 COPD patients at baseline and after 6 and 30 months of fluticasone\u00b1salmeterol and placebo treatment in GLUCOLD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: We searched PubMed for placebo-controlled studies evaluating long-term (\u226524 weeks) use of formoterol, salmeterol, or indacaterol in patients with stable COPD, published between January 1990 and September 2012. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Where analyzed as an efficacy outcome, LABA treatment was generally associated with significant or numerical reductions in COPD exacerbations compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Incidences of COPD-related adverse events were similar for active and placebo treatments. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Simulations suggested a maximum placebo-corrected increase of 2.7 (0.90-4.82)\u2009beats\u2009min(-1) in COPD patients for a PF-00610355 dose of 280\u2009\u03bcg once daily, with 19% subjects experiencing a heart rate increase of more than 20\u2009beats\u2009min(-1) compared with 8% in the placebo group. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Fifteen randomized, placebo-controlled clinical trials including COPD patients were evaluated: indacaterol 75 \u03bcg once daily (n = 2 studies), indacaterol 150 \u03bcg once daily (n = 5), indacaterol 300 \u03bcg once daily (n = 4), FOR/BUD 9/160 \u03bcg twice daily (n = 2), FOR/BUD 9/320 \u03bcg twice daily (n = 2), SAL/FP 50/500 \u03bcg twice daily (n = 4), and SAL/FP 50/250 \u03bcg twice daily (n = 1). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " BACKGROUND: The objective of this study was to evaluate the comparative efficacy of indacaterol 75 \u03bcg once daily (OD), tiotropium 18 \u03bcg OD, salmeterol 50 \u03bcg twice daily (BID), formoterol 12 \u03bcg BID, and placebo for the treatment of chronic obstructive pulmonary disease (COPD) based on individual patient data (IPD) from randomized controlled trials (RCTs) from the indacaterol trial program and aggregate data (AD) identified from a systematic review of RCTs. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The cost-effectiveness studies of tiotropium versus placebo, ipratropium or salmeterol pointed towards a reduction in total COPD-related healthcare costs for tiotropium in many but not all studies. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In short-term trials (\u226421 days) in patients with COPD, once-daily indacaterol 150 or 300\u2009\u03bcg significantly improved lung function, exercise endurance and lung hyperinflation relative to placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In large, longer-term clinical studies (12 weeks to 1 year) in patients with moderate to severe COPD, once-daily indacaterol 150 or 300\u2009\u03bcg improved lung function (primary endpoint) significantly more than placebo, and improvements were significantly greater than twice-daily formoterol 12\u2009\u03bcg or salmeterol 50\u2009\u03bcg, and noninferior to once-daily tiotropium bromide 18\u2009\u03bcg (all agents were administered via inhalation). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The most common adverse event in clinical trials was COPD worsening, which occurred more commonly with placebo than indacaterol. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Ten COPD and 10 healthy subjects were treated with salmeterol or placebo 4\u00a0h before the patient's mechanical and diffusive lung properties were measured during four non consecutive days, just before and after a rapid saline infusion, or during a similar period without an infusion.RESULTS: In both COPD and healthy subjects, rapid saline infusion with placebo or salmeterol premedication lead to a significant decrease in diffusion capacity for carbon monoxide (DLCO) and forced expiratory volume in 1\u00a0s (FEV1). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: In this multicentre, double-blind, double-dummy, placebo-controlled, three-way single-dose crossover study, patients \u226540 years of age with moderate COPD were randomized to single-dose formoterol 9\u2009\u03bcg via Turbuhaler\u00ae plus placebo via Diskus\u00ae, single-dose salmeterol 50\u2009\u03bcg via Diskus\u00ae plus placebo via Turbuhaler\u00ae or placebo via Turbuhaler\u00ae and Diskus\u00ae (washout period 2-7 days). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Shorter-term placebo-controlled trials in patients with COPD demonstrated significantly higher trough forced expiratory volume in 1 second (FEV(1)) responses with tiotropium bromide than with placebo, confirming it has a duration of action of \u226524 hours and is suitable for once-daily administration. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The large, 4-year UPLIFT\u00ae trial did not show a significant reduction in the annual rate of decline in FEV(1) with tiotropium bromide versus placebo in patients with COPD, although subgroup analyses demonstrated a significantly lower rate of decline with tiotropium bromide than with placebo in some patient groups (e.g. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Tiotropium bromide prevented exacerbations in patients with COPD, with a significantly lower exacerbation rate and a significantly longer time to first exacerbation seen with tiotropium bromide than with placebo or salmeterol. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 \u00b5g/500 \u00b5g combination (SFC), or placebo in a 12-week, randomized, double-blind, double-dummy study (MKI102428/NCT00642148). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "PATIENTS AND METHODS: Data were pooled from clinical studies of 3-12 months' duration in patients with moderate-to-severe COPD receiving double-blind indacaterol 75 \u03bcg (n = 449), 150 \u03bcg (n = 2611), 300 \u03bcg (n = 1157), or 600 \u03bcg once daily (n = 547); formoterol 12 \u03bcg twice daily (n = 556); salmeterol 50 \u03bcg twice daily (n = 895); placebo (n = 2012); or tiotropium 18 \u03bcg once daily, given open label or blinded (n = 1214). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "RESULTS: The commonest adverse events with indacaterol were COPD worsening, nasopharyngitis, and headache; most cases were mild or moderate and incidence was generally similar to placebo and other active treatments. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "COPD exacerbation rates (analyzed in the intent-to-treat population) were significantly reduced with all active treatments versus placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The evidence reviewed comprises four placebo-controlled clinical studies of indacaterol treatment, three of which included treatment arms with one of the other long-acting inhaled bronchodilators (once-daily tiotropium or twice-daily salmeterol or formoterol), in 4,833 patients with moderate-to-severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In four large (n\u2009>\u2009400), randomized, double-blind, placebo-controlled, multicentre phase III trials, patients with COPD who received indacaterol 150 or 300\u2009\u03bcg once daily had a significantly higher mean trough forced expiratory volume in 1 second (FEV\u2081) than placebo recipients after 12 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "COPD exacerbations and symptoms, and health-related quality of life were also significantly improved for indacaterol versus placebo recipients in some studies. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: this study compared the onset of action of single doses of indacaterol 150 and 300 \u03bcg with salbutamol 200 \u03bcg, salmeterol-fluticasone 50/500 \u03bcg, and placebo in moderate-to-severe COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients with moderate-to-severe COPD were randomised to 6 months double-blind treatment with indacaterol (150 \u03bcg once daily), salmeterol (50 \u03bcg twice daily) or placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "This decision was based, in part, on the results of several large, international, multicenter, randomized, placebo-controlled trials of either six or 12 months' duration that had been undertaken in COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Roflumilast 500 mug daily improved lung function and reduced exacerbations in patients with more severe COPD, especially those with chronic bronchitis, frequent exacerbations, or who required frequent rescue inhaler therapy in the placebo-controlled trials. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Across four randomized, double-blind, multinational trials in patients with moderate to severe or severe COPD, roflumilast 500 microg/day produced significantly greater improvements from baseline than placebo in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV(1)). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In three of four trials, roflumilast significantly reduced the COPD exacerbation rate; in a pooled analysis of two 52-week trials, roflumilast was associated with a 17% reduction over placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Here we compared the 24-h spirometry profile of once daily indacaterol 300 \u03bcg with that of placebo and twice daily salmeterol 50 \u03bcg in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients (male/female \u2265 40 years) with moderate-to-severe COPD were randomized to receive double-blind indacaterol 300 \u03bcg or placebo once daily, or open-label salmeterol 50 \u03bcg twice daily. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In chronic respiratory diseases in general, and chronic obstructive pulmonary disease (COPD) in particular, adherence to inhaled therapy can potentially influence disease prognosis, as demonstrated in the analyses discussed in this article and a 3-year study assessing the effects of inhaled salmeterol, inhaled fluticasone and an inhaled combination over placebo in patients with moderate-to-severe COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral roflumilast 500 microg or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: In a randomized, double-blind, placebo-controlled, crossover study of moderate/severe stable COPD patients, we compared the effects of 4 weeks of treatment with salmeterol 50 microg b.d. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: TORCH was a 3-year, double-blind, placebo-controlled trial of 6112 patients with moderate/severe COPD with pre-bronchodilator FEV1 < 60% predicted (mean age 65 years, 76% male, mean 44% predicted FEV1, 43% current smokers). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSIONS: Compared with control (placebo or salmeterol), tiotropium did not significantly increase the risk of adverse major cardiovascular events among COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a post hoc analysis of the TOwards a Revolution in COPD Health (TORCH) study, we analysed and identified potential risk factors for adverse event reports of pneumonia in this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 microg, fluticasone propionate (FP) 500 microg, and the combination (SFC) with placebo in 6,184 patients with moderate-to-severe COPD over 3 yrs. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "STUDY DESIGN: A Markov model was constructed to estimate the incremental quality-adjusted life-years (QALYs) gained of the alternative treatment arms used in the Towards a Revolution in COPD Health (TORCH) study (ie, salmeterol-fluticasone propionate combination [SFC], salmeterol, fluticasone, and placebo). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "An increased risk of pneumonia with inhaled corticosteroids was first reported from the Toward Revolution in COPD Health (TORCH) study, a large randomized clinical trial comparing fluticasone, salmeterol, or a combination of the two medications with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Several large-scale studies in patients with moderate-to-severe COPD have demonstrated that treatment with SFC and FBC leads to significantly greater improvements in lung function, exacerbations, health status and breathlessness, compared with placebo or monotherapy with the component drugs. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Having previously shown that specific airway conductance (sGaw) measured using body plethysmography and impulse oscillometry (IOS) are more sensitive than FEV(1) for assessing short-acting bronchodilator effects in patients with COPD, we conducted the first randomized, placebo-controlled study to compare long-acting bronchodilators in COPD patients using these techniques. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: In this double-blind, randomized, four-way crossover study, 32 COPD patients received single doses of Tio (18 microg), S (50 and 100 microg) or placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a randomised, double-blind, placebo-controlled crossover trial, 20 patients with COPD performed two ESWT at 80% of peak capacity 2.5 h after inhaling either a placebo or 50 microg of salmeterol. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Four double-blind, placebo-controlled, randomized clinical trials have demonstrated that salmeterol/fluticasone propionate improves pulmonary function and health status, and also decreases exacerbation rates in COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Male and female patients aged >or=35 years with physician-diagnosed COPD received arformoterol (15 microg BID, 25 microg BID, or 50 microg QD via nebulizer), salmeterol (42 microg BID via metered dose inhaler), or placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "There was a similar frequency of AEs and COPD exacerbations across all groups, including placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSIONS: In this trial, patients with moderate to severe COPD administered nebulized arformoterol over 12 weeks were observed to have significant and sustained improvements in airway function and dyspnea compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " BACKGROUND: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol combination treatment and its monotherapy components for maintenance treatment of moderately to severely impaired patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Tiotropium plus fluticasone-salmeterol improved lung function (P = 0.049) and disease-specific quality of life (P = 0.01) and reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53 [CI, 0.33 to 0.86]) and all-cause hospitalizations (incidence rate ratio, 0.67 [CI, 0.45 to 0.99]) compared with tiotropium plus placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "A meta-analysis was therefore conducted to review studies in COPD to provide pooled estimates of the effect of salmeterol 50 mcg taken twice daily in addition to usual therapy on several clinically relevant endpoints, when compared with placebo/usual therapy. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Nine randomized, double-blind, parallel-group, placebo-controlled trials of > or =12 week duration with salmeterol 50 mcg bid treatment in COPD were included (>3500 patients), with a further 14 trials excluded due to study design or reporting timelines. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "A recent individual patient-based meta-analysis of randomized, placebo-controlled trials of inhaled corticosteroids in COPD indicated that mortality over 3-4 yr was 27% lower in the group that received inhaled corticosteroids compared with the group that received placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "SELECTION CRITERIA: All RCTs comparing inhaled LABAs (salmeterol or formoterol) with placebo in the treatment of patients with stable, poorly reversible COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: 634 patients aged >40 years with a history of COPD exacerbations (including at least two in the previous year) and poor reversibility of airflow obstruction (< or =10% predicted forced expiratory volume in 1 second) received either salmeterol 50 mug or placebo twice daily from a Diskus inhaler for 12 months. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In clinical trials, patients receiving tiotropium 18 microg QD had significant improvements in trough, peak, and mean forced expiratory volume in 1 second (FEV1), dyspnea, and health-related quality of life, as well as fewer COPD exacerbations and hospitalizations, compared with patients receiving placebo and ipratropium (all, P < 0.05). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The aim of this study was to assess the short term efficacy and safety of 50 and 100 microg bid inhaled salmeterol, compared with placebo and orally dose titrated slow-release theophylline in patients with stable COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "RESULTS: Inhaled salmeterol at both tested doses was better than placebo in improving lung function (FEV1, FVC, and morning PEF) of stable patients with moderate COPD over a period of 2 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: The Canadian Optimal Therapy of COPD Trial is a randomized, prospective, double-blind, placebo-controlled, multicentre trial funded by the Canadian Institutes of Health Research that has been designed to determine which combination of inhaled medications will most effectively prevent exacerbations and optimize disease-specific quality of life in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The study will randomize 432 patients with moderate to severe COPD to one of three parallel treatment arms for 52 weeks: tiotropium and fluticasone/salmeterol; tiotropium and salmeterol; or tiotropium and placebo inhaler. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSION: The present randomized, placebo-controlled trial offers a unique opportunity to answer the question, what is the best combination of inhaled medications to use for COPD patients? It is hoped that optimal use of inhaled medications will improve patient health and quality of life, reduce patient respiratory exacerbations, and ultimately, reduce health care resource use. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In this study, we have performed additional analyses of the combined data from two previous double-blind, placebo-controlled, parallel studies of salmeterol (50 microg, b.i.d) in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a sensitivity analysis, we compared 539 male and 180 female COPD patients, who were randomized to the saLmeterol/fluticasone combination 50/500mcg bid or placebo for 12 months. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease (COPD), by reviewing long-term prospective studies in which these drugs have been compared with placebo or an alternative bronchodilator. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In patients with COPD, both salmeterol and formoterol offer improved lung function and reduced COPD symptoms compared with placebo, and quality of life has been improved in some studies. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "We reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in patients with poorly reversible COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Some corticosteroid-related adverse events were increased in recipients of fluticasone propionate with or without salmeterol versus salmeterol monotherapy or placebo; withdrawal from fluticasone propionate, including combination therapy, needs careful management to minimise COPD exacerbations. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a randomised double-blind crossover study, 23 patients with COPD (mean +/- SEM forced expiratory volume in one second 42 +/- 3% of the predicted value) inhaled salmeterol 50 microg or placebo twice daily for 2 weeks each. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Sixteen patients with \"irreversible\" COPD (<10% improvement in FEV(1) following a bronchodilator challenge; mean FEV(1) 31.1% predicted) were recruited into a randomised, double blind, placebo controlled, crossover study of salmeterol (50 micro g twice a day). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In three randomized, double-blind, 24-week or 52-week studies in >2850 patients with chronic obstructive pulmonary disease (COPD), administration of salmeterol/fluticasone propionate 50/250 microg twice daily (in one study) and salmeterol/fluticasone propionate 50/500 microg twice daily (in the other studies) provided greater improvement in lung function than placebo or either component alone at the same nominal dosage. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The role of inhaled corticosteroids still remains controversial, but there is increasing evidence that they may improve FEV(1) and symptoms in the long-term.AIM: of the present small pilot study was to compare Salmeterol & Fluticasone (SM&FP) 50/250 microg bid via a single Diskus inhaler with SM 50 microg bid alone, and with placebo (P) in the treatment of moderate COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a retrospective analysis of a cohort of 997 COPD patients who received tiotropium, salmeterol or placebo, in addition to usual care, the validity and pattern of response of the BDI and TDI were examined. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The aim of the present study was to compare the acute effect of four inhaled bronchodilators (salbutamol, formoterol, salmeterol and oxitropium) and placebo on forced expiratory volume in one second, inspiratory capacity, forced vital capacity and dyspnoea in COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "A cross-over, randomised, double-blind, placebo-controlled study was carried out on 20 COPD patients. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients with smoking-related COPD were required to complete a 2-week baseline period before being randomized to one of three treatment groups; sibenadet (500 microg three times daily) plus placebo (twice daily); salmeterol (50 microg twice daily) plus placebo (three times daily); placebo (twice daily) plus a second placebo (three times daily). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients with a history of COPD were randomised to treatment with salmetrol 50 mcg (229 patients) or placebo (227 patients) twice daily administered by metered-dose inhaler in addition to normal therapy. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "A total of 691 patients with COPD received the combination of F and S (FSC), S (50 mcg), F (500 mcg), or placebo twice daily via the Diskus device for 24 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "SELECTION CRITERIA: All RCTs over four weeks in duration comparing treatment with long-acting beta-2 adrenoceptor agonists (salmeterol or formoterol) with placebo in patients with stable poorly-reversible COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "All eight assessed the efficacy of salmeterol in COPD compared to placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: To compare the effect of adding salmeterol (50 microg bid) or placebo to concurrent anticholinergic therapy on symptom scores, quality of life, prebronchodilator lung function and exacerbations in patients with moderately severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In patients with chronic obstructive pulmonary disease (COPD), tiotropium 18microg once daily significantly improved lung function compared with placebo and ipratropium 40microg four times daily in 1-year trials or salmeterol 50microg twice daily in a 6-month study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The incidence of COPD exacerbations decreased and use of rescue medication was lower with tiotropium compared with placebo or ipratropium. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Sixteen patients with moderate to severe chronic obstructive pulmonary disease (COPD) and 10 non-smoker asthmatic patients received 40 mg of oral zafirlukast, 50 microg of inhaled salmeterol, 50 microg of inhaled salmeterol plus 40 mg of oral zafirlukast of placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The drug has been compared with placebo, ipratropium bromide and oral theophylline in patients with chronic obstructive pulmonary disease (COPD) in randomised, clinical trials. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Compared with placebo, inhaled salmeterol 50 microg twice daily alone, or concurrent with ipratropium bromide 40 microg 4 times daily improved lung function and reduced symptoms in patients with stable COPD in a 12-week, randomised, double-blind study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "SELECTION CRITERIA: All randomised controlled trials over four weeks in duration comparing treatment with long-acting beta2-adrenoceptor agonists (salmeterol and formoterol) with placebo in patients with stable non-reversible COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " Thirty patients of stable chronic obstructive pulmonary disease (COPD) were studied for evaluation of effectiveness of inhaled salmeterol in a double blind, randomised, placebo controlled trial for seven days. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: One hundred and forty four patients with moderate or severe COPD were randomly assigned to receive three months of treatment with either salmeterol, salmeterol + ipratropium bromide, or placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: In a double-blind, randomized, crossover and placebo-controlled study design, the respiratory functions of 22 patients (mean age 57.3+/-5.4 years) having mild to severe COPD (5 mild, 8 moderate and 9 severe) and partially reversible airway obstruction [mean baseline reversibility of forced expiratory volume in 1 s (FEV(1)) 19.3+/-3.1%] were evaluated after inhalation of 12 microg formoterol and 50 microg salmeterol. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " To compare the effects of salmeterol, an adrenergic drug, and ipratropium bromide, an anticholinergic drug, on breathlessness and gas exchange during exercise in patients with chronic obstructive lung disease (COPD), we performed a progressive treadmill exercise test on 15 patients on 3 days (24 h apart), after inhalation placebo, ipratropium bromide (120 micrograms) or salmeterol (50 micrograms) in a randomized fashion. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Sixteen outpatients with partially reversible, stable COPD received 24 microg formoterol, 50 microg salmeterol, 200 microg oxitropium bromide, or placebo on four non-consecutive days. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " The objectives of this study were to compare the efficacy and safety of salmeterol xinafoate (50 and 100 microg b.i.d.) with that of placebo, when added to existing therapy, in the treatment of patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " Changes in health-related quality of life (HRQoL) were evaluated in patients with chronic obstructive pulmonary disease (COPD) following treatment with placebo, salmeterol 50 microg twice a day or 100 microg twice a day by metered-dose inhaler. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "To investigate the efficacy of salmeterol in smokers with COPD a double blind, randomised, crossover comparison was performed between salmeterol (50 micrograms twice daily) and placebo in 63 patients with stable COPD (mean age 63 yrs); inclusion criteria: aFEV1) < 60% of predicted and FEV1 reversibility < 15% (0.4 mg salbutamol). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " Bronchodilator efficacy of salbutamol (200 micrograms), salmeterol (50 micrograms) and ipratropium bromide (40 micrograms) aerosols has been compared in 16 patients with stable chronic obstructive pulmonary disease (COPD) using a double-blind placebo controlled cross-over design. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: To investigate the efficacy of salmeterol in smokers with moderate to severe COPD a double blind, randomised, crossover comparison was performed between salmeterol (50 micrograms twice daily) and placebo in 63 patients with stable COPD (mean age 65 years). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSIONS: This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " In the present trial we investigated the time course of inhaled salmeterol and formoterol bronchodilation in comparison with that of inhaled salbutamol and placebo in 16 patients with moderate to severe chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "We aimed to derive this by analyzing data from three existing COPD clinical trials of budesonide/formoterol, formoterol, or placebo in patients with moderate-to-very-severe COPD and a history of exacerbations in the previous year. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "MATERIALS AND METHODS: COPD patients (n=40), mean FEV1 58% predicted normal, received single-dose inhaled formoterol 9\u03bcg, or placebo, followed by 8 weeks treatment bid with a combination of budesonide and formoterol Turbuhaler(\u00ae) 320/9\u03bcg or formoterol Turbuhaler(\u00ae). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Twelve patients with Global Initiative for Chronic Obstructive Lung Disease stage II COPD were randomized to receive NAC 1800 mg or placebo daily for 3 months and were then crossed over to the alternative treatment for a further 3 months. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: To determine the efficacy and safety of combined ICS and LABA for stable COPD in comparison with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "AUTHORS' CONCLUSIONS: Combined inhaler therapy led to around a quarter fewer COPD exacerbations than were seen with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting \u03b22-agonists (ICS/LABA). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Fifteen randomized, placebo-controlled clinical trials including COPD patients were evaluated: indacaterol 75 \u03bcg once daily (n = 2 studies), indacaterol 150 \u03bcg once daily (n = 5), indacaterol 300 \u03bcg once daily (n = 4), FOR/BUD 9/160 \u03bcg twice daily (n = 2), FOR/BUD 9/320 \u03bcg twice daily (n = 2), SAL/FP 50/500 \u03bcg twice daily (n = 4), and SAL/FP 50/250 \u03bcg twice daily (n = 1). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Budesonide/formoterol Turbuhaler\u00ae improved lung function, exacerbation rates, COPD symptom scores and health status from baseline to a significantly greater extent than placebo and, in general, than the individual monotherapies in these trials. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Shorter-term placebo-controlled trials in patients with COPD demonstrated significantly higher trough forced expiratory volume in 1 second (FEV(1)) responses with tiotropium bromide than with placebo, confirming it has a duration of action of \u226524 hours and is suitable for once-daily administration. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The large, 4-year UPLIFT\u00ae trial did not show a significant reduction in the annual rate of decline in FEV(1) with tiotropium bromide versus placebo in patients with COPD, although subgroup analyses demonstrated a significantly lower rate of decline with tiotropium bromide than with placebo in some patient groups (e.g. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Tiotropium bromide prevented exacerbations in patients with COPD, with a significantly lower exacerbation rate and a significantly longer time to first exacerbation seen with tiotropium bromide than with placebo or salmeterol. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: This 12-week, randomised, double-blind, placebo-controlled, Phase IIb, trial (NCT01023516), investigated the efficacy and safety of AZD9668 (60 mg bid) versus placebo in patients with symptomatic COPD and a history of exacerbation receiving maintenance budesonide/formoterol. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Data were from 2 randomized, double-blind, placebo-controlled studies (6-months [NCT00206154]; 12-months [NCT00206167]) in patients with moderate to very severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVE: To evaluate retrospectively over a 3-month period, the cost effectiveness of budesonide/formoterol added to tiotropium bromide (tiotropium) compared with placebo added to tiotropium in COPD patients eligible for ICS/LABA combination therapy, based on the CLIMB study (NCT00496470). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: A cost-effectiveness analysis of data from the 12-week, randomized, double-blind CLIMB study of COPD patients (n\u2009=\u2009659; eligible for ICS/LABA; aged \u2265 40 years) comparing budesonide/formoterol (Symbicort\u00ae Turbuhaler\u00ae 320/9 \u03bcg twice daily) added to tiotropium (18 \u03bcg daily) or placebo added to tiotropium was conducted. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSION: Budesonide/formoterol added to tiotropium was the dominant strategy compared with placebo added to tiotropium based on a 12-week study in COPD patients eligible for ICS/LABA combination therapy in Australia and Canada, and appears to be a cost-effective strategy in Sweden. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: We pooled patient data from seven large clinical trials of inhaled budesonide (320-1280 mug/day), with or without formoterol, versus control regimen (placebo or formoterol alone) in patients with stable COPD and at least 6 months of follow-up. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Two hundred and fifty-four current smokers with COPD were randomised to treatment with either an inhaled corticosteroids (ICS), budesonide 400 microg bid, or placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: This was a 12-month, randomized, double-blind, double-dummy, parallel-group, active- and placebo-controlled, multicentre study (NCT00206167) of 1, 964 patients aged >or =40 years with moderate to very severe COPD conducted from 2005 to 2007 at 237 sites in the US, Europe and Mexico. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The rate of COPD exacerbations was lower in both budesonide/formoterol groups compared with formoterol and placebo (p <or= 0.004). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Forty-five patients not using steroids (37 male, 21/24 current/ex smoker, median packyears 38, age 65 years, FEV(1) 61% predicted), experiencing a COPD exacerbation, were treated at home with budesonide/formoterol (320/9 microg 4 times daily), prednisolone (30 mg daily), or placebo for 14 days. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Four prospective placebo-controlled clinical trials of 2-6 years duration with inhaled budesonide in patients with asthma or COPD were found. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: This was a 6-month, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicentre study (NCT00206154) of 1704 patients aged > or =40 years with moderate to very severe COPD conducted in 194 centres in the US, Czech Republic, the Netherlands, Poland and South Africa. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The incidence of individual non-fatal serious adverse events was similar across all treatment groups, except COPD, which was highest in the budesonide/formoterol 320/9 microg group (6.1%) and lowest in the budesonide (3.6%) and formoterol (3.9%) groups, with a range of 4.3-4.6% in the budesonide/formoterol 160/9 microg, budesonide plus formoterol and placebo groups. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Several large-scale studies in patients with moderate-to-severe COPD have demonstrated that treatment with SFC and FBC leads to significantly greater improvements in lung function, exacerbations, health status and breathlessness, compared with placebo or monotherapy with the component drugs. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The current authors performed a post hoc analysis of the European Respiratory Society's study on Chronic Obstructive Pulmonary Disease (EUROSCOP); a 3-yr, placebo-controlled study of an inhaled corticosteroid budesonide 800 microg.day(-1) in smokers (mean age 52 yrs) with mild COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Twenty-six patients with stable COPD were randomised, in a double-blinded, placebo-controlled trial with either 800 microg of inhaled budesonide or placebo for a 6-month period. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " OBJECTIVE: To compare the healthcare costs and effects of budesonide/formoterol in a single inhaler with those of budesonide and formoterol monotherapies, and placebo, in a multinational study in patients with chronic obstructive pulmonary disease (COPD), National Heart, Lung and Blood Institute (NHLBI)/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages III or IV. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "budesonide 800 microg/day or fluticasone propionate 1 mg/day) reduce exacerbations by 20-30% and improve the health status of COPD patients by a similar amount compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In two large, randomised, double-blind, 12-month studies, patients with severe chronic obstructive pulmonary disease (COPD) receiving budesonide/formoterol 320/9 microg twice daily had a significantly higher forced expiratory volume in 1 second (FEV1) and significantly higher morning and evening peak expiratory flow at trial endpoint than recipients of budesonide or placebo; FEV1 was significantly higher than with formoterol in the larger study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In both studies, the rate of COPD exacerbations and exacerbations requiring oral corticosteroids was significantly reduced with budesonide/formoterol versus formoterol and placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Patients (n=912, mean age 52 yrs) with mild COPD (mean forced expiratory volume in one second (FEV1) 77% of predicted; mean FEV1/slow vital capacity ratio 62%) were randomized to receive budesonide 400 microg, or placebo twice daily via Turbuhaler. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In this multicenter, double-blind, randomized, placebo-controlled trial, the efficacy of nebulized budesonide (Pulmicort Respules/Nebuamp), oral prednisolone, and placebo was compared in 199 patients with acute exacerbations of COPD requiring hospitalization. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " We compared the effect of inhaled budesonide with placebo on decline in lung function and respiratory symptoms in a three-year study of patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In a double-blind, placebo-controlled study, we evaluated the effect of the inhaled glucocorticoid budesonide in patients with mild COPD who continued smoking. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: In phase I patients with stable COPD were given a two week course of oral placebo followed by two weeks of prednisone 40 mg per day in a single blind manner to distinguish between responders and non-responders to oral corticosteroids. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In 44 patients with stable COPD in a double- blind crossover trial, we compared a 6-week course of inhalations of 800 micrograms/d budesonide with a placebo, separated by a 4-week interval when no medication was taken. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Compared to placebo, a 12-week treatment of the long-acting beta-agonist, indacaterol might not have a significant effect on cough or phlegm in stable COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: A double-blind crossover trial was performed to compare the treatment of COPD patients with an SABA (20 \u00b5g of inhaled procaterol) versus a placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Randomized clinical trials pertaining to the treatment of COPD with the combination of umeclidinium and vilanterol, versus umeclidinium, vilanterol or placebo, were reviewed. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "placebo, umeclidinium and vilanterol, umeclidinium plus vilanterol improves lung function and quality of life in patients with COPD, reduces the use of albuterol, and does not increase the incidence of adverse events and serious adverse events. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": " BACKGROUND: The combination of the inhaled muscarinic antagonist umeclidinium (UMEC) with the long-acting \u03b22-agonist vilanterol (VI) has been shown to provide significant improvements in lung function compared with UMEC, VI, or placebo (PBO) in patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In two 12-week, double-blind, parallel-group studies, patients with COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 \u03bcg and 125 \u03bcg) or placebo (PBO), added to twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 \u03bcg). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "We compared the efficacy and safety of UMEC/VI with placebo in patients with COPD of Asian ancestry. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "CONCLUSION: In Asian patients with COPD, once-daily UMEC/VI 125/25 \u03bcg and UMEC 62.5/25 \u03bcg resulted in clinically meaningful and statistically significant improvements in lung-function end points versus placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Separate randomized, double-blind, parallel-arm, placebo-controlled trials compared two administrations of inhaled loxapine (10\u2009mg) 10\u2009hr apart with placebo in 52 subjects with asthma and in 53 subjects with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Symptomatic bronchospasm occurred in 53.8% of subjects with asthma after inhaled loxapine and 11.5% after placebo; and in 19.2% of COPD subjects after inhaled loxapine and 11.1% after placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Subjects required inhaled albuterol as follows: asthma: 53.8% after inhaled loxapine and 11.5% after placebo; and COPD: 23.1% after inhaled loxapine and 14.8% after placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "OBJECTIVES: To compare the efficacy and safety of once-daily umeclidinium/vilanterol (UMEC/VI) 125/25 mcg with placebo and UMEC or VI monotherapy in COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Patients with moderate to severe COPD were randomized to receive double-blind treatment with indacaterol 75 \u03bcg once daily (n = 163 and 159) or placebo (n = 160 and 159) for 12 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Data were pooled from three randomized, double-blind, clinical studies in patients with moderate-to-severe COPD treated with indacaterol 150 \u03bcg qd (n = 627) or placebo (n = 1021). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Worsening of COPD was the most frequent adverse event (10% indacaterol; 15% placebo). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Data were from 2 randomized, double-blind, placebo-controlled studies (6-months [NCT00206154]; 12-months [NCT00206167]) in patients with moderate to very severe COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "METHODS: Following a run-in period of 7-14 days with once-daily TIO 18 microg, COPD subjects (> or =25% to <65% predicted forced expiratory volume in 1 second [FEV(1)]) were randomized to twice-daily FFIS 20 microg (n=145) or nebulized placebo (PLA, n=140) while continuing on maintenance TIO for 6 weeks. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "COPD patients receiving open-label tiotropium bromide 18 microg once daily during a 1- to 2-week run-in period were randomized to receive either formoterol fumarate inhalation solution 20 microg or placebo by nebulization twice daily for 6 weeks while continuing treatment with tiotropium. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Physician and patient global COPD ratings and the EQ-5D visual analog scale scores were improved with tiotropium (p<0.05); as-needed albuterol was reduced by 25% relative to placebo (p<0.05). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Statistically significant and clinically relevant (>120 ml) improvements in lung function [assessed using standardized/normalized area under the forced expiratory volume in 1 second (FEV1) versus time curve (AUC FEV1)] were observed with inhaled formoterol 12 microg twice daily (the approved dosage in the US) compared with placebo in 12-week and 12-month, randomized, double-blind trials in patients with chronic obstructive pulmonary disease (COPD). "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Importantly, there were no significant differences between formoterol and placebo or comparator drugs in cardiovascular adverse events in patients with COPD and corrected QT interval values within the normal range. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "In conclusion, inhaled formoterol improved lung function and health-related quality of life and reduced symptoms relative to placebo in clinical trials in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "SELECTION CRITERIA: Studies were selected for inclusion if they compared treatment with heliox to placebo (oxygen or air) in randomized controlled trials in adults with an exacerbation of COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "The drug has been compared with placebo, ipratropium bromide and oral theophylline in patients with chronic obstructive pulmonary disease (COPD) in randomised, clinical trials. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Compared with placebo, inhaled salmeterol 50 microg twice daily alone, or concurrent with ipratropium bromide 40 microg 4 times daily improved lung function and reduced symptoms in patients with stable COPD in a 12-week, randomised, double-blind study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "REVIEWER'S CONCLUSIONS: There are few controlled trial data concerning the use of inhaled beta2-agonist agents in acute exacerbations of COPD and none that have compared these agents directly with placebo. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Eleven patients with COPD inhaled albuterol or placebo in a double-blind randomized manner. "}, {"drug": "placebo", "polarity": 0, "disease": "COPD", "orig_sen": "Twenty-two male COPD patients (64+/-6 years old, FEV1: 49+/-20%) received an IV infusion of 2 g of magnesium sulfate or placebo on two distinct occasions. "}]